UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter's lead asset NRTX-1001 to its epilepsy portfolio.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
Pharmaceutical Technology
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.
